

Appendix Table 9. Effects of Anticholinergic Drugs Compared with Placebo on Self-Reported Urinary Continence or Improvement in UI in Women with Overactive Bladder (90)*

Author Year	Active Treatment	Control Treatment	(Events/Active Treatment) [Events / Control Treatment]	Relative Risk (95% CI)	Risk Difference (95%CI)	Quality
Burgio†, 1998 (174)	Oxybutynin 5- 10mg	Placebo	(45/55) [34/52]	1.25 (0.99; 1.58)	0.16 (0.00; 0.33)	Intention to treat. Modified crossover design (extension of a randomized double blind clinical trial). Allocation concealment adequate. Sample size justified
DuBeau, 2005(91)	Tolterodine ER 4 mg	Placebo	(383/569) [134/285]	1.43 (1.25; 1.64)	0.20 (0.13; 0.27)	Not Intention to treat. Double blind. Allocation concealment adequate. Sample size justified
Diokno, 2003(92)	Oxybutynin ER 10 mg	Tolterodine ER 4mg	(90/391) [67/399]	1.37 (1.03; 1.82)	0.06 (0.01; 0.12)	Intention to treat. Double blind. Allocation concealment unclear. Sample size not justified
Khullar, 2004†(93)	Tolterodine ER 4 mg	Placebo	(347/569) [131/285]	1.33 (1.15; 1.53)	0.15 (0.08; 0.22)	Intention to treat. Double-blind. Randomization by permuted blocks. Allocation concealment adequate. Sample size justified
Anderson, 1999(94)	Oxybutynin controlled release 5-20mg	Oxybutynin IR 5mg	(4/53) [8/52]	0.49 (0.16; 1.53)	-0.08 (-0.20; 0.04)	Not Intention to treat Double-blind. Allocation concealment unclear. Sample size not justified

*Bold - significant relative risk at 95% confidence level. ER = extended release; IR = immediate release.

† included in the review (90).